Juice Plus Supplement Clinical Trial
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04656860 |
Recruitment Status : Unknown
Verified June 2020 by University of Alabama, Tuscaloosa.
Recruitment status was: Recruiting
First Posted : December 7, 2020
Last Update Posted : April 8, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cognitive Impairment Alzheimer Disease, Early Onset Mild Cognitive Impairment | Dietary Supplement: Juice Plus+ | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 150 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Participants will be randomized to experimental or placebo controlled condition |
Masking: | Double (Participant, Investigator) |
Masking Description: | Both the investigator and the participants will be blinded to study conditions |
Primary Purpose: | Prevention |
Official Title: | Encapsulated Fruit and Vegetable Juice Concentrates, Cognition, and Inflammation - A Randomized Placebo-controlled Trial |
Actual Study Start Date : | March 12, 2020 |
Estimated Primary Completion Date : | March 12, 2022 |
Estimated Study Completion Date : | March 12, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Juice Plus+
Participants will consume 6 capsules daily consisting of a combination of Juice Plus+ Garden Blend, Juice Plus+ Orchard Blend and Juice Plus+ Berry Blend. Participants will consume supplements for 24-months.
|
Dietary Supplement: Juice Plus+
Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period |
Placebo Comparator: Placebo
Participants will consume 6 capsules daily consisting of microcrystalline cellulose, rice starch, vegetarian capsule (cellulose), and magnesium stearate. Participants in this condition will receive 1-year of supplements after the study is completed.
|
Dietary Supplement: Juice Plus+
Participants will receive encapsulated fruit and vegetable juice concentrates or a placebo for a 24-month period |
- Change in Interleukin -5 [ Time Frame: Baseline, Year, 1, and Year 2. ]Interleukin -5 pg/mL
- Change in serum Amyloid A [ Time Frame: Baseline, Year, 1, and Year 2. ]Serum Amyloid A pg/mL
- Change in Interleukin 6 [ Time Frame: Baseline, Year, 1, and Year 2. ]Interleukin 6 pg/mL
- Change in C-reactive protein [ Time Frame: Baseline, Year, 1, and Year 2. ]C-reactive protein pg/mL
- Auditory Very Learning Test [ Time Frame: Baseline, 6-months, 12-months, 18-months, and 24-months ]Computer automated verbal memory recognition task
- Stroop Test [ Time Frame: Baseline, 6-months, 12-months, 18-months, and 24-months ]Verbal interference
- Trial Making task [ Time Frame: Baseline, 6-months, 12-months, 18-months, and 24-months ]Information processing speed

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 55 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- • Men and women ≥55 years old will be eligible participants
Exclusion Criteria:
- Prior neurological or psychiatric condition
- Using medications or supplements that influence cognition or inflammation (e.g., nootropics, asprin, and Nonsteroidal anti-inflammatory drugs,),
- Prior cancer diagnosis,
- Major respiratory, kidney, liver, and gastrointestinal issues
- Currently enrolled in a weight loss program or taking an appetite suppressant;
- Current smokers or excessive alcohol users
-
Consume >= 4 servings of fruits and vegetables per day
- Participate in >= 90 minutes of purposeful physical activity per week
- Do not have a mobile phone
- Do not have a data plan or regular wireless network

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04656860
Contact: Raheem Paxton, PhD | 205-348-6857 | rpaxton@ua.edu |
United States, Alabama | |
University of Alabama, North East Medical Building | Recruiting |
Tuscaloosa, Alabama, United States, 35487 | |
Contact: Raheem Paxton, PhD 205-348-6857 rpaxton@ua.edu | |
University of Alabama | Recruiting |
Tuscaloosa, Alabama, United States, 35487 | |
Contact: Raheem Paxton, PhD 205-348-6857 rpaxton@ua.edu | |
Contact: Raheem Paxton, PhD 204-348-6857 rpaxton@ua.edu |
Principal Investigator: | Raheem Paxton, PhD | University of Alabama at Birmingham |
Responsible Party: | University of Alabama, Tuscaloosa |
ClinicalTrials.gov Identifier: | NCT04656860 |
Other Study ID Numbers: |
17-19-490 |
First Posted: | December 7, 2020 Key Record Dates |
Last Update Posted: | April 8, 2021 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Plan Description: | Individual data will not be shared with other researchers |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Fruits and Vegetables Inflammation Cognition |
Alzheimer Disease Cognitive Dysfunction Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases |
Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Cognition Disorders |